[A22-137] Abemaciclib (breast cancer; combination with an aromatase inhibitor) – Benefit assessment according to §35a Social Code Book V
Last updated 03.04.2023
Project no.:
A22-137
Commission:
Commission awarded on 22.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Postmenopausal women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who have not yet received initial endocrine-based therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-51 | Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-153 | Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-73 | Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-72 | Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-32 | Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V | Commission completed |